一點思考
關於學術會議
美羅華簡史
一段有關一個傳奇藥物的歷史，一段有關患者的故事，一段感悟
改變臨床實踐的臨床研究- IMpower 010
IMpower010 是一項隨機 3 期研究。完全切除的 ⅠB（≥4 cm）～ⅢA 期 NSCLC 患者在行含鉑方案輔助化療後，隨機接受輔助阿替利珠單抗治療 1 年（16 週期）或最佳支持治療（BSC）。
Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response
Tumor cells evade immune surveillance by upregulating the surface expression of programmed death-ligand 1 (PD-L1), which interacts with programmed death-1 (PD-1) receptor on T cells to elicit the immune checkpoint response. Anti-PD-1 antibodies have shown remarkable promise in treating tumors, including lung cancer and metastatic melanoma. However, there is a problem that PD-1/PD-L1 blockade is associated with a response rate is low. A better understanding of PD-L1-mediated immune evasion is needed to predict patient response and improve treatment efficacy.
Notebook: Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy
Immunotherapy combined with PD-1 and CTLA-4 is effective for renal melanoma and non-small cell lung cancer.However, thiscomes at the cost of frequent, serious immune-related adverseevents, necessitating a reduction in the recommended dose ofipilimumab that is given to patients. Immune-related adverse events that result from therapy with checkpoint inhibitors are usually satisfactorily treated by discontinuing theuse of the therapeutic agents and beginning a course of steroids. However, after stopping the use of checkpoint inhibitors, the tumor could not be treated.